false
Catalog
Leveraging Knowledge of Clozapine's Pharmacodynami ...
Presentation Slides
Presentation Slides
Back to course
Pdf Summary
This document is a summary of the content found in a webinar titled "Leveraging Knowledge of Clozapine’s Pharmacodynamics and Pharmacokinetics to Improve Outcomes," presented by an APA and SAMHSA Initiative. The webinar discusses the use of clozapine in the treatment of serious mental illness, focusing on its pharmacodynamics and pharmacokinetics.<br /><br />Clozapine is the only medication approved by the FDA for the treatment of treatment-resistant schizophrenia (TRS). It has unique efficacy in TRS, but its mechanism of action is not fully understood. Clozapine is an antagonist at D2, H1, alpha1, M1, and M3 receptors, and a partial agonist at 5HT1A receptors. It also has a high affinity for D4 receptors.<br /><br />The webinar highlights the importance of understanding the pharmacokinetics of clozapine, including its absorption, distribution, metabolism, and excretion. Clozapine has a bioavailability of 27-50% and reaches peak plasma concentration within 2 hours. It takes 5-7 days to reach steady state and is metabolized by the CYP1A2 enzyme.<br /><br />The webinar also emphasizes the potential side effects of clozapine, including neutropenia, myocarditis, seizures, sedation, tachycardia, orthostatic hypotension, constipation, hyperphagia/weight gain, and sialorrhea. It provides management strategies for these side effects, such as regular monitoring, dose adjustments, and medication changes.<br /><br />In conclusion, the webinar highlights the importance of understanding the pharmacodynamics and pharmacokinetics of clozapine to optimize its use and improve patient outcomes. It provides valuable information for healthcare professionals prescribing and monitoring clozapine in the treatment of serious mental illness.
Keywords
Clozapine
Pharmacodynamics
Pharmacokinetics
Treatment-resistant schizophrenia
Antagonist
Partial agonist
Bioavailability
CYP1A2 enzyme
Side effects
Patient outcomes
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
×
Please select your language
1
English